Details of the Drug

General Information of Drug (ID: DM6Q7U4)

Drug Name

Lenalidomide

Synonyms

Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1], [2], [3], [4]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

259.26

Topological Polar Surface Area (xlogp)

-0.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [5]
Elimination: 66% of drug is excreted from urine in the unchanged form [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.375 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.00045 mg/mL [5]

Chemical Identifiers

Formula: C13H13N3O3
IUPAC Name: 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
Canonical SMILES: C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
InChI: InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey: GOTYRUGSSMKFNF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 216326
ChEBI ID: CHEBI:63791
CAS Number: 191732-72-6
DrugBank ID: DB00480
TTD ID: D0Q5NX
VARIDT ID: DR00261
ACDINA ID: D00353

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Multiple myeloma

ICD Disease Classification

2A83

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tumor necrosis factor (TNF)	DTT	TNF	8.51E-01	0.05	0.27
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.08E-01	-2.87E-01	-5.57E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.05E-01	1.60E-01	1.37E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lenalidomide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[27]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Lenalidomide due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[27]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[28]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Roflumilast.	Asthma [CA23]	[27]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[29]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Lenalidomide and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[30]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[31]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Cannabidiol.	Epileptic encephalopathy [8A62]	[27]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[32]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[33]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Lenalidomide and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[35]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Lenalidomide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[36]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Methotrexate.	Leukaemia [2A60-2B33]	[27]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Denosumab.	Low bone mass disorder [FB83]	[37]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[38]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[39]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Idelalisib.	Mature B-cell leukaemia [2A82]	[40]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[41]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Lenalidomide and Siponimod.	Multiple sclerosis [8A40]	[42]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Lenalidomide and Fingolimod.	Multiple sclerosis [8A40]	[43]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Ocrelizumab.	Multiple sclerosis [8A40]	[44]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Lenalidomide and Ozanimod.	Multiple sclerosis [8A40]	[27]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[45]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[46]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Lenalidomide due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[47]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Canakinumab.	Rheumatoid arthritis [FA20]	[48]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Rilonacept.	Rheumatoid arthritis [FA20]	[48]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Lenalidomide and Golimumab.	Rheumatoid arthritis [FA20]	[49]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Lenalidomide and Leflunomide.	Rheumatoid arthritis [FA20]	[36]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Lenalidomide when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[50]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[27]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Lenalidomide and Naltrexone.	Substance abuse [6C40]	[51]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Lenalidomide due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[52]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Lenalidomide and Azathioprine.	Transplant rejection [NE84]	[42]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Lenalidomide and Ganciclovir.	Virus infection [1A24-1D9Z]	[42]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Lenalidomide and Valganciclovir.	Virus infection [1A24-1D9Z]	[42]
-----------


⏷ Show the Full List of 37 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lenalidomide 10 mg capsule	10 mg	Oral Capsule	Oral
Lenalidomide 15 mg capsule	15 mg	Oral Capsule	Oral
Lenalidomide 2.5 mg capsule	2.5 mg	Oral Capsule	Oral
Lenalidomide 20 mg capsule	20 mg	Oral Capsule	Oral
Lenalidomide 25 mg capsule	25 mg	Oral Capsule	Oral
Lenalidomide 5 mg capsule	5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
2	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	BDDCS applied to over 900 drugs
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
8	The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99.
9	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
10	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
12	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
14	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
15	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
16	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
17	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
18	Clinical pipeline report, company report or official report of AstraZeneca (2009).
19	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
20	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
21	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
22	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
23	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
24	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
25	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
26	TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
27	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
29	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
30	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
32	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
33	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
34	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
35	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
36	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
37	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
38	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
39	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
40	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
41	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
42	Cerner Multum, Inc. "Australian Product Information.".
43	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
44	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
45	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
47	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
48	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
49	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
50	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
51	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
52	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.